Salivary Biomarkers in Alzheimer´s Disease

Código QR

Salivary Biomarkers in Alzheimer´s Disease

SUMMARY: The hypotheses currently considered the most likely causes of Alzheimer's disease (AD) are amyloid beta peptide deposition in the cerebral cortex and hyperphosphorylation of the Tau protein, with the consequent formation of neurofibrillary tangles. In clinical practice, although not ac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Santos,Gustavo A. A, Olave,Enrique, Pardi,Paulo C
Lenguaje:	English
Publicado:	Sociedad Chilena de Anatomía 2020
Materias:	Alzheimer’s disease Biomarkers Amyloid beta-peptide Saliva Tau protein Dementia
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022020000100230
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
por: Vyronia Vassilakopoulou, et al.
Publicado: (2021)

Alzheimer's disease and blood-based biomarkers – potential contexts of use
por: Zvěřová M
Publicado: (2018)

Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum
por: Nathalie I. V. Nilsson, et al.
Publicado: (2021)

Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
por: Tiwari S, et al.
Publicado: (2019)

Alzheimer disease: 100 years later
por: Puglielli MD,Luigi, et al.
Publicado: (2001)

Histidines 13 and 14 in the Aβ sequence are targets for inhibition of Alzheimer's disease Aβ ion channel and cytotoxicity
por: DÍAZ,JUAN CARLOS, et al.
Publicado: (2006)

All roads lead to Rome — a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer’s disease
por: Yi-Yao Liang, et al.
Publicado: (2022)

Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention
por: Guimei Zhang, et al.
Publicado: (2021)

Effect of Curcumin on Beta-Amyloid Plasma Level in Alzheimer Disease: A Systematic Review and Meta-analysis
por: Shima Mehrabadi, et al.
Publicado: (2021)

Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study
por: So Hee Park, et al.
Publicado: (2021)

Long noncoding RNAs and Alzheimer's disease
por: Luo Q, et al.
Publicado: (2016)

Attenuative Effects of Fluoxetine and <i>Triticum aestivum</i> against Aluminum-Induced Alzheimer’s Disease in Rats: The Possible Consequences on Hepatotoxicity and Nephrotoxicity
por: Karema Abu-Elfotuh, et al.
Publicado: (2021)

Liposome delivery systems for the treatment of Alzheimer’s disease
por: Ross C, et al.
Publicado: (2018)

Association between Sleep, Alzheimer’s, and Parkinson’s Disease
por: Sumire Matsumoto, et al.
Publicado: (2021)

Alzheimer's disease: Newer biomarkers
por: Ankit Dangi, et al.
Publicado: (2021)

Alzheimer’s Disease Determination by a Dual Probe on Gold Nanourchins and Nanohorn Hybrids
por: Qiu Z, et al.
Publicado: (2021)

Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis
por: Giacomo Stroffolini, et al.
Publicado: (2021)

Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer’s Disease
por: Mar Cuadrado-Tejedor, et al.
Publicado: (2021)

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
por: Longfei Jia, et al.
Publicado: (2021)

Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
por: Carely Hernandez, et al.
Publicado: (2022)

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles
por: Xing Y, et al.
Publicado: (2017)

Higher Plasma APOC-III Was Associated with a Slower Reduction of β-Amyloid Levels in Cerebrospinal Fluid Among Older Individuals Without Dementia
por: Zhang X
Publicado: (2020)

Iron Homeostasis Disorder and Alzheimer’s Disease
por: Yu Peng, et al.
Publicado: (2021)

Enzymatic Methods for Salivary Biomarkers Detection: Overview and Current Challenges
por: Alonso Ornelas-González, et al.
Publicado: (2021)

APOE GENE POLYMORPHISM: THE IMPACT OF APOE4 ALLELE ON SYSTEMIC INFLAMMATION AND ITS ROLE IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE
por: I. K. Malashenkova, et al.
Publicado: (2018)

Administration of anti-ERMAP antibody ameliorates Alzheimer’s disease in mice
por: Haiyan Liu, et al.
Publicado: (2021)

Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease
por: Zhang YY, et al.
Publicado: (2013)

An insight into Alzheimer’s disease and its on-setting novel genes
por: Jaanaky Vigneswaran, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Sherif Bayoumy, et al.
Publicado: (2021)

Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder
por: Cai Z, et al.
Publicado: (2013)

Model Identifies Genetic Predisposition of Alzheimer’s Disease as Key Decider in Cell Susceptibility to Stress
por: Ioanna C. Stefani, et al.
Publicado: (2021)

Biomarcadores y Marcadores de Imagen de la Enfermedad de Alzheimer
por: Pardi,P.C, et al.
Publicado: (2017)

Biomarkers in Alzheimer’s disease
por: Janeiro Manuel H., et al.
Publicado: (2020)

The genetics of Alzheimer's disease
por: Bagyinszky E, et al.
Publicado: (2014)

Type 2 diabetes as a risk factor for cognitive impairment: current insights
por: Umegaki H
Publicado: (2014)

Study of Histopathological Lesions in CA1 of the Hippocampus after Injection of Beta-Amyloid in a Rat Model of Alzheimer’s Disease
por: SM Hoseini,, et al.
Publicado: (2012)

Analysis of salivary proteomic biomarkers for the surveillance of changes in high-risk status of early childhood caries
por: Xinzhu Zhou, et al.
Publicado: (2021)

Perspectivas en la prevención y tratamiento farmacológico de la enfermedad de Alzheimer
por: Archibaldo Donoso,S, et al.
Publicado: (2009)

Amyloid-ß-peptide reduces copper(II) to copper(I) independent of its aggregation state
por: OPAZO,CARLOS, et al.
Publicado: (2000)

Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
por: Ruiqing Ni
Publicado: (2021)